Free Trial

Telesis Bio Q2 2024 Earnings Report

Telesis Bio logo
$0.47 -0.09 (-16.07%)
(As of 12/20/2024 03:47 PM ET)

Telesis Bio EPS Results

Actual EPS
-$7.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Telesis Bio Revenue Results

Actual Revenue
$1.55 million
Expected Revenue
$6.50 million
Beat/Miss
Missed by -$4.95 million
YoY Revenue Growth
N/A

Telesis Bio Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>

Telesis Bio Earnings Headlines

Telesis Bio Announces Departure of Chief Legal Officer
The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
See More Telesis Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Telesis Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Telesis Bio and other key companies, straight to your email.

About Telesis Bio

Telesis Bio (NASDAQ:TBIO), a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

View Telesis Bio Profile

More Earnings Resources from MarketBeat

Upcoming Earnings